# US 11,110,181 B2 · Virus-like particle conjugates for diagnosis and treatment of tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,181 B2
- Document ID: US11110181B2
- Status: Granted
- Kind: B2
- Application number: 16/778,361
- Filed: 2020-01-31
- Published: 2020-06-18
- Granted: 2021-09-07
- Earliest claimed: 2013-09-18
- Assignees: Aura Biosciences, Inc.; The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicants: Aura Biosciences, Inc.; The United States of America, as represented by the Secretary, Department of Health and Human Serv.
- Inventors: Elisabet de los Pinos; John Todd Schiller; Rhonda C. Kines; John MacDougall
- Web page: https://patentgrep.com/patent/US11110181B2

## CPC

- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 39/12: Viral antigens
- A61K 41/0057: {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- A61K 41/0071: {PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 1/13: Labelling of peptides
- C07K 14/025: Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- C07K 16/084: Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
- C07K 16/32: against translation products of oncogenes
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/585: {wherein the target is cancer}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2710/20023: Virus like particles [VLP]
- C12N 2710/20033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.

## Claims

### Claim 1

A tumor-targeting virus-like particle comprising papilloma virus capsid proteins and 50 to 1000 photosensitive molecules conjugated to the capsid proteins, wherein the photosensitive molecules comprise (a) a photosensitive molecule that becomes toxic or produces a toxic molecule upon activation by light and (b) a photosensitive molecule that does not become toxic or produce a toxic molecule upon activation by light.

### Claim 2 (depends on 1)

The virus-like particle of claim 1, wherein the papilloma virus capsid proteins are non-human papilloma virus capsid proteins.

### Claim 3 (depends on 2)

The virus-like particle of claim 2, wherein the non-human papilloma virus capsid proteins comprise L1 capsid proteins.

### Claim 4 (depends on 3)

The virus-like particle of claim 3, wherein the non-human papilloma virus capsid proteins consist of L1 capsid proteins.

### Claim 5 (depends on 1)

The virus-like particle of claim 1, wherein the photosensitive molecules are covalently conjugated to the capsid proteins.

### Claim 6

A method comprising delivering to a subject a tumor-tropic virus-like particle comprising papilloma virus capsid proteins and 50 to 1000 photosensitive molecules conjugated to the capsid proteins, wherein the photosensitive molecules comprise (a) a photosensitive molecule that becomes toxic or produces a toxic molecule upon activation by light and (b) a photosensitive molecule that does not become toxic or produce a toxic molecule upon activation by light.

### Claim 7 (depends on 6)

The method of claim 6, wherein the subject has a bladder tumor.

### Claim 8 (depends on 6)

The method of claim 6, wherein the papilloma virus capsid proteins are non-human papilloma virus capsid proteins.

### Claim 9 (depends on 8)

The method of claim 8, wherein the non-human papilloma virus capsid proteins comprise L1 capsid proteins.

### Claim 10 (depends on 9)

The method of claim 9, wherein the non-human papilloma virus capsid proteins consist of L1 capsid proteins.

### Claim 11 (depends on 6)

The method of claim 6, wherein the photosensitive molecules are covalently conjugated to the capsid proteins.

### Claim 12 (depends on 6)

The method of claim 6, further comprising activating the photosensitive molecule of (b) at a wavelength of light that permits visualization of the photosensitive molecule of (b).

### Claim 13 (depends on 6)

The method of claim 6, further comprising activating the photosensitive molecule of (a) at a wavelength of light that causes the photosensitive molecule of (a) to become toxic or produce a toxic molecule.

### Claim 14 (depends on 6)

The method of claim 6, wherein the virus-like particle is delivered by injection.